ABBV is trading near the top of its 52-week range and above its 200-day simple moving average. Price change The price of ABBV shares has decreased $5.14 since the market last closed. This is a 2.00% ...

The stock is up just 8% this year and could prove to be an undervalued buy.

With a market cap of $443.4 billion, AbbVie Inc. (ABBV) is a biopharmaceutical company focused on discovering and delivering ...

AbbVie (NYSE: ABBV), a pharmaceutical giant, is set to release its first-quarter earnings report on April 29. The stock has not performed well so far this year, with shares down 13% as of writing.

When I last checked on pharmaceutical stock AbbVie (ABBV) in January, a price correction was on the cards, as the company was due to sign the MFN agreement and its market multiples were elevated too.

AbbVie pays a more modest yield, but it has been increasing its dividend at a high rate in recent years. Pfizer, meanwhile, pays a much higher amount and can be attractive to investors who don't want ...

AbbVie Inc. (ABBV), the North Chicago, Illinois-based Pharma giant, is expected to report its Q1 2026 earnings around April 29th - in just under three weeks' time. A few days ago, AbbVie released an 8 ...

AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.